The Journal of ExtraCorporeal Technology No 56-2 | Page 33

60 D . C . Fitzgerald et al .: J Extra Corpor Technol 2024 , 56 , 55 – 64
Table 3 . Cardioplegia details .
Overall
Year
p-value
Missing
2019
2020
2021
2022
Number of cases
40,777
10,261
9295
9731
11,490
Use of cardioplegia
< 0.001
0.1
Yes , cardioplegia
39,211 ( 96.3 )
9832 ( 95.9 )
8901 ( 95.8 )
9392 ( 96.7 )
11,086 ( 96.7 )
Yes , ventricular fibrillation
36 ( 0.1 )
10 ( 0.1 )
6 ( 0.1 )
4 ( 0.0 )
16 ( 0.1 )
None
1470 ( 3.6 )
409 ( 4.0 )
382 ( 4.1 )
319 ( 3.3 )
360 ( 3.1 )
Cardioplegia regime
< 0.001
4.2
Continuous
5094 ( 13.0 )
1339 ( 13.7 )
1272 ( 14.3 )
1245 ( 13.3 )
1238 ( 11.2 )
Intermittent
32,745 ( 83.8 )
8454 ( 86.3 )
7615 ( 85.7 )
8051 ( 86.3 )
8625 ( 78.0 )
Single dose
1239 ( 3.2 )
0 ( 0.0 )
0 ( 0.0 )
38 ( 0.4 )
1201 ( 10.9 )
Number of doses , median
3.00 [ 2.00 , 6.00 ]
3.00 [ 2.00 , 6.00 ]
4.00 [ 2.00 , 6.00 ]
3.00 [ 2.00 , 6.00 ]
3.00 [ 2.00 , 6.00 ]
< 0.001
8.1
Total cardioplegia volume ( mL ), median
2100.0 [ 1250.0 ,
2150.0 [ 1250.0 ,
2288.5 [ 1279.5 ,
2100.0 [ 1200.0 ,
2000.0 [ 1227.0 ,
< 0.001
5.1
3400.0 ]
3500.0 ]
3750.0 ]
3400.0 ]
3100.0 ]
Cardioplegia category
< 0.001
3.3
None
395 ( 1.0 )
109 ( 1.1 )
93 ( 1.0 )
92 ( 1.0 )
101 ( 0.9 )
1:1
1 ( 0.0 )
0 ( 0.0 )
1 ( 0.0 )
0 ( 0.0 )
0 ( 0.0 )
2:1
4 ( 0.0 )
1 ( 0.0 )
1 ( 0.0 )
1 ( 0.0 )
1 ( 0.0 )
4:1
6689 ( 17.0 )
1809 ( 18.3 )
1357 ( 15.2 )
1348 ( 14.3 )
2175 ( 19.5 )
8:1
5592 ( 14.2 )
1572 ( 15.9 )
1431 ( 16.0 )
1324 ( 14.0 )
1265 ( 11.3 )
Crystalloid
123 ( 0.3 )
43 ( 0.4 )
50 ( 0.6 )
29 ( 0.3 )
1 ( 0.0 )
Variable
2148 ( 5.4 )
561 ( 5.7 )
516 ( 5.8 )
448 ( 4.7 )
623 ( 5.6 )
Crystalloid ( custodial )
841 ( 2.1 )
337 ( 3.4 )
200 ( 2.2 )
113 ( 1.2 )
191 ( 1.7 )
Microplegia
7687 ( 19.5 )
1666 ( 16.9 )
2063 ( 23.0 )
2129 ( 22.5 )
1829 ( 16.4 )
del Nido
15,835 ( 40.1 )
3770 ( 38.2 )
3236 ( 36.1 )
3941 ( 41.7 )
4888 ( 43.8 )
Other
122 ( 0.3 )
9 ( 0.1 )
8 ( 0.1 )
23 ( 0.2 )
82 ( 0.7 )
Induction routes
< 0.001
5
Antegrade-aortic root
35,281 ( 91.1 )
8617 ( 88.3 )
8019 ( 90.8 )
8520 ( 92.3 )
10,125 ( 92.8 )
Antegrade-coronary ostium
513 ( 1.3 )
123 ( 1.3 )
124 ( 1.4 )
138 ( 1.5 )
128 ( 1.2 )
Retrograde
2935 ( 7.6 )
1017 ( 10.4 )
691 ( 7.8 )
575 ( 6.2 )
652 ( 6.0 )
Maintenance route Antegrade-aortic root
18,684 ( 62.6 )
4783 ( 63.6 )
4210 ( 60.2 )
4298 ( 60.2 )
5393 ( 65.9 )
< 0.001
26.8
Antegrade-coronary ostium ( left , right ,
2347 ( 7.9 )
583 ( 7.7 )
527 ( 7.5 )
501 ( 7.0 )
736 ( 9.0 )
< 0.001
26.8
or both )
Antegrade-bypass graft
2936 ( 9.8 )
650 ( 8.6 )
720 ( 10.3 )
752 ( 10.5 )
814 ( 9.9 )
< 0.001
26.8
Retrograde
15,631 ( 52.4 )
4055 ( 53.9 )
3838 ( 54.9 )
3869 ( 54.2 )
3869 ( 47.2 )
< 0.001
26.8
Terminal warm reperfusate
< 0.001
4.4
No
22,647 ( 58.1 )
5867 ( 60.1 )
4915 ( 55.5 )
5167 ( 55.5 )
6698 ( 60.5 )
Yes , standard
1203 ( 3.1 )
355 ( 3.6 )
357 ( 4.0 )
330 ( 3.5 )
161 ( 1.5 )
Yes , Buckberg
124 ( 0.3 )
15 ( 0.2 )
68 ( 0.8 )
27 ( 0.3 )
14 ( 0.1 )
Yes , blood only
10,312 ( 26.4 )
2406 ( 24.6 )
2503 ( 28.2 )
2729 ( 29.3 )
2674 ( 24.2 )
Yes , combination
4424 ( 11.3 )
1125 ( 11.5 )
1019 ( 11.5 )
1037 ( 11.1 )
1243 ( 11.2 )
Yes , microplegia
293 ( 0.8 )
0 ( 0.0 )
0 ( 0.0 )
13 ( 0.1 )
280 ( 2.5 )
Continuous variables are expressed as median , [ IQR ], and categorical variables as count (%).
traditionally been used to establish benchmarks for cardiovascular perfusion , including establishing trends in practice patterns [ 14 , 15 ], gaining consensus on essential clinical skills [ 16 ], and reporting adverse intraoperative incidents [ 17 ]. Unfortunately , this methodological approach is subject to bias , including recall bias ( when asking a respondent to recall the number of instances of a particular adverse outcome ) and survey bias ( survey respondents versus non-respondents may differ in known and unknown ways ). While the distribution of surveys provides the opportunity to amass large analytical datasets , investigators have reported variable survey response rates focused on both the cardiac surgical program ( 35 %– 100 %) [ 14 , 15 ] and perfusionist levels ( 52 %– 69 %) [ 17 – 19 ]. As such , one of the distinct contributions of the present report is the establishment of benchmarks that derive from clinical registry data whose denominators are validated against institutional STS-ACSD harvest files . The validation against the STS-ACSD is important to minimize bias in data submitted by PERForm participants .
This first annual report highlights several emerging trends in CPB practices . The most recent 2021 STS / SCA / AmSECT / SABM patient blood management guidelines identified several evidence-based perfusion interventions , including retrograde autologous priming ( RAP ), reduced CPB priming volume , and acute normovolemic hemodilution ( ANH ) [ 20 ]. While the present report documents that 85.8 % of procedures utilized RAP , its use decreased marginally over the study period ( 2019 vs . 2022 : 86.5 % vs . 83.4 %, p < 0.001 ). An observational study of participating PERForm hospitals in 2014 found RAP usage in the setting of isolated CABG was 71.4 %, suggesting a 21 % increase over the last 7 years [ 21 ]. The median ( IQR ) net prime volume indexed to a patient ’ s body surface area increased from 321.3 ml / m 2 ( 278.3 – 394.9 ) in 2019 to 349.2 ml / m 2 ( 288.4 %– 429.9 %) in 2022 , p < 0.001 . A previous PERForm analysis